Article Navigation
Article Contents
-
Abstract
- < Previous
- Next >
Journal Article
, M Hauguel-Moreau University Hospital Ambroise Pare , Boulogne-Billancourt , France Search for other works by this author on: Oxford Academic D Mansencal University Hospital Ambroise Pare , Boulogne-Billancourt , France Search for other works by this author on: Oxford Academic K Miliani CHU Raymond Poincaré, Epidemiology , Garches , France Search for other works by this author on: Oxford Academic A Beauchet University Hospital Ambroise Pare , Boulogne-Billancourt , France Search for other works by this author on: Oxford Academic C Rodon CPAM Hauts de Seine, Epidemiology , Nanterre , France Search for other works by this author on: Oxford Academic O Dubourg University Hospital Ambroise Pare , Boulogne-Billancourt , France Search for other works by this author on: Oxford Academic N Mansencal University Hospital Ambroise Pare , Boulogne-Billancourt , France Search for other works by this author on: Oxford Academic
Funding Acknowledgements: None.
Author Notes
European Journal of Preventive Cardiology, Volume 31, Issue Supplement_1, June 2024, zwae175.355, https://doi.org/10.1093/eurjpc/zwae175.355
Published:
13 June 2024
- Split View
- Views
- Article contents
- Figures & tables
- Video
- Audio
- Supplementary Data
-
Cite
Cite
M Hauguel-Moreau, D Mansencal, K Miliani, A Beauchet, C Rodon, O Dubourg, N Mansencal, Statin therapy eligibility in a large primary prevention cohort according to European Society of Cardiology Guidelines, European Journal of Preventive Cardiology, Volume 31, Issue Supplement_1, June 2024, zwae175.355, https://doi.org/10.1093/eurjpc/zwae175.355
Close
Search
Abstract
Background
2016 European Society of Cardiology (ESC) guidelines on statin therapy eligibility in primary prevention were updated in 2021, with significant differences and particularly the use of a new estimation of 10-year fatal and nonfatal CVD risk with Systematic Coronary Risk Estimation 2 (SCORE2).
Purpose
The aim of the study was to compare the proportion of subjects aged 40 to 69 years eligible to statin therapy according to the 2016 and 2021 ESC recommendations in a large primary prevention cohort.
Methods
We conducted a screening campaign between January 2007 and December 2022 for cardiovascular risk factors in large urban cohort of subjects aged 40-69 (the CARVAR 92 study). We systematically calculated the individual cardiovascular risk for all our subjects. We thus estimated the proportion of subjects eligible for statin therapy based on 2021 ESC guidelines versus 2016 ESC guidelines. Costs relating to statin therapy were also estimated.
Results
27,807 subjects were included in the CARVAR 92 study: 13.7% were eligible to statin therapy according to the 2016 ESC guidelines versus 32.2% according to the 2021 guidelines (p < 0.0001). The proportion of subjects eligible to statin therapy increased by a factor 2.3 between the 2016 and 2021 ESC guidelines for the whole cohort, and increased by a factor 12 in men aged 40 to 50 (from 3.8% of individuals eligible to statin therapy for 2016 recommendation to 45.7% [p < 0.0001] for 2021 recommendation). Costs associated with statin therapy for the whole cohort increased by a 2.7 factor between 2016 and 2021 recommendations.
Conclusion
In a large primary prevention cohort, we observed a strong increase in the number of subjects eligible to statin therapy with the new 2021 ESC recommendations (versus 2016) and therefore in statin costs, particularly in men between 40 and 50 years old. The clinical and economic impact on the occurrence of cardiovascular events of these new recommendations in a real life remains to be evaluated.
Eligibilty to statin therapy.
Open in new tabDownload slide
This content is only available as a PDF.
Author notes
Funding Acknowledgements: None.
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
Issue Section:
Preventive Cardiology > Risk Factors and Prevention > Lipids
Download all slides
Comments
0 Comments
Comments (0)
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.
Advertisem*nt intended for healthcare professionals
Citations
Views
Altmetric
More metrics information
Metrics
Total Views 0
0 Pageviews
0 PDF Downloads
Since 6/13/2024
Citations
Powered by Dimensions
Altmetrics
Email alerts
Article activity alert
Advance article alerts
New issue alert
Receive exclusive offers and updates from Oxford Academic
Citing articles via
Google Scholar
-
Latest
-
Most Read
-
Most Cited
More from Oxford Academic
Cardiovascular Medicine
Clinical Medicine
Medicine and Health
Books
Journals
Advertisem*nt intended for healthcare professionals